Clinical Trials

335 enrolled

Myeloproliferative Disorders, Leukemia, Myeloid, Acute

NCT05564390 2026-05-26

MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)

2,000 enrolled

Phase 1 Active not recruiting

Myelodysplastic Syndromes, Myeloproliferative Disorders, Leukemia, Myeloid, Acute

NCT02632708 2026-05-22

Safety Study of AG-120 or AG-221 in Combination With Induction and Consolidation Therapy in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) With an IDH1 and/or IDH2 Mutation

153 enrolled

Leukemia, Myeloid, Acute

NCT03629171 2026-05-20

Liposome-encapsulated Daunorubicin-Cytarabine and Venetoclax in Treating Participants With Relapsed, Refractory or Untreated Acute Myeloid Leukemia

52 enrolled

Leukemia, Myeloid, Acute

NCT04915612 2026-05-20

Liposomal Cytarabine, Daunorubicin, and Gemtuzumab Ozogamicin for the Treatment of Relapsed Refractory Pediatric Patients With Acute Myeloid Leukemia

Phase 1 Completed

1 enrolled

Leukemia, Myeloid, Acute

NCT03900949 2026-05-15

Gentuzumab Ozogamicin and Midostaurin Combination With Standard Cytarabine and Danunorubi Midostaurin as a Novel Approach to Treating Patients With Newly Diagnosed FLT-3 Mutated Acute Myeloid Leukemia

Phase 1 Completed

21 enrolled

Leukemia, Myeloid, Acute

NCT05554393 2026-05-15

Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)

153 enrolled

Leukemia, Myeloid, Acute

NCT04195945 2026-05-14

CPX-351 or CLAG-M Regimen for the Treatment of Acute Myeloid Leukemia or Other High-Grade Myeloid Neoplasms in Medically Less-Fit Patients

60 enrolled 19 charts

Leukemia, Monocytic, Acute, Leukemia, Myeloid, Acute

NCT06635681 2026-05-13

DAV-AML-2024

380 enrolled

Leukemia, Myeloid, Acute

NCT04801797 2026-05-12

Venetoclax + Azacitidine vs. Induction Chemotherapy in AML

172 enrolled

Leukemia, Myeloid, Acute

NCT07007312 2026-05-12

Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML

1,300 enrolled

Phase 1 Active not recruiting

Leukemia, Leukemia, Myeloid, Acute, Hematologic Neoplasms

NCT05453903 2026-05-08

A Study of Bleximenib in Combination With Acute Myeloid Leukemia (AML) Directed Therapies

196 enrolled

Leukemia, Myeloid, Acute

NCT04293562 2026-05-05

A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations

1,186 enrolled

Leukemia, Myeloid, Acute

NCT07561892 2026-05-01

AML

Phase 4 Recruiting

100 enrolled

Leukemia, Myeloid, Acute

NCT06497062 2026-04-30

Phase II Study of Sonrotoclax Combined With Chemotherapy in the Treatment of Newly Diagnosed Acute Myeloid Leukemia

47 enrolled

Leukemia, Myeloid, Acute

NCT06578247 2026-04-30

QuANTUM-WILD

700 enrolled

Leukemia, Leukemia, Myeloid, Acute

NCT01627041 2026-04-27

Decitabine, Cytarabine, and Daunorubicin Hydrochloride in Treating Patients With Acute Myeloid Leukemia

178 enrolled

Leukemia, Monocytic, Acute, Leukemia, Myeloid, Acute, Leukemia, Basophilic, Acute, Leukemia, Myelomonocytic, Acute

NCT03591510 2026-04-27

A Global Study of Midostaurin in Combination With Chemotherapy to Evaluate Safety, Efficacy and Pharmacokinetics in Newly Diagnosed Pediatric Patients With FLT3 Mutated AML

22 enrolled

Leukemia, Myeloid, Acute

NCT03164057 2026-04-23

A Trial of Epigenetic Priming in Patients With Newly Diagnosed Acute Myeloid Leukemia

206 enrolled

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT05955261 2026-04-23

A Study of Venetoclax in Combination With Conventional Chemotherapy in Pediatric Patients With Acute Myeloid Leukemia

Phase 2 Suspended

70 enrolled

Leukemia, Myeloid, Acute

NCT04214249 2026-04-13

BLAST MRD AML-1: BLockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease in Acute Myeloid Leukemia 1- A Randomized Phase 2 Study of Anti-PD-1 Pembrolizumab in Combination With Intensive Chemotherapy as Frontline Therapy in Patients With Acute Myeloid Leukemia

49 enrolled 32 charts

Phase 2 Not yet recruiting

Leukemia, Myeloid, Acute

NCT05554419 2026-04-13

Testing the Use of Combination Therapy in Patients With Persistent Low Level Acute Myeloid Leukemia Following Initial Treatment, The ERASE Study (A MyeloMATCH Treatment Trial)

184 enrolled

Leukemia, Myeloid, Acute

NCT07223814 2026-04-06

Bleximenib in Combination With Standard Induction and Consolidation Therapy Followed by Maintenance for Treatment of Patients With Acute Myeloid Leukemia (AML)

875 enrolled

Leukemia, Myeloid, Acute

NCT06313437 2026-03-25

Revumenib in Combination With 7+3 + Midostaurin in AML

22 enrolled

Phase 3 Not yet recruiting

Leukemia, Leukemia, Myeloid, Acute

NCT07407140 2026-03-25

VAG-3+7-G

300 enrolled

Leukemia, Myeloid, Acute

NCT02971397 2026-03-23

Cytarabine and Daunorubicin Hydrochloride in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia

Phase 1 Completed

40 enrolled 21 charts

Leukemia, Myeloid, Acute

NCT05735184 2026-03-13

A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML

Other hematologic neoplasmSarcoma

420 enrolled

Leukemia, Leukemia, Myeloid, Acute, Hematologic Neoplasms, Sarcoma, Myeloid

NCT05627232 2026-03-12

Tazemetostat and Palbociclib With CPX-351for R/R AML

24 enrolled

Leukemia, Myeloid, Acute

NCT04231851 2026-03-06

CPX-351 and Glasdegib for Newly Diagnosed Acute Myelogenous Leukemia With MDS Related Changes or Therapy-related Acute Myeloid Leukemia

30 enrolled 15 charts

Phase 2/3 Not yet recruiting

Leukemia, Myeloid, Acute

NCT07255872 2026-03-05

A Study of BL-M11D1 in Combination With Cytarabine + Daunorubicin or Venetoclax + Azacitidine in Patients With Acute Myeloid Leukemia

216 enrolled

Leukemia, Myeloid, Acute

NCT07132684 2026-03-02

Comparison of VA and D/IA Induction Regimens in Elderly Fit Acute Myeloid Leukemia Patients

240 enrolled

Leukemia, Myeloid, Acute

NCT03826992 2026-02-18

Venetoclax Combined With Vyxeos (CPX-351) for Participants With Relapsed or Refractory Acute Leukemia

21 enrolled

Leukemia, Recurrence, Leukemia, Myeloid, Acute

NCT05656248 2026-02-04

Study of CPX-351 (VYXEOS) in Individuals < 22 Years With Secondary Myeloid Neoplasms

25 enrolled

Phase EARLY_PHASE1 Completed

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Juvenile

NCT03568994 2026-01-27

ATACC AML

26 enrolled

Leukemia, Myeloid, Acute

NCT07228273 2026-01-22

Induction and Consolidation With Fludarabine, Cytarabine, Idarubicin, and Venetoclax for the Treatment of Acute Myeloid Leukemia

102 enrolled

Phase 2/3 Active not recruiting

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT03701308 2026-01-21

Daunorubicin and Cytarabine With or Without Uproleselan in Treating Older Adult Patients With Acute Myeloid Leukemia Receiving Intensive Induction Chemotherapy

267 enrolled 11 charts

Phase 1 Active not recruiting

Leukemia, Myeloid, Acute

NCT03709758 2026-01-16

Venetoclax in Combination With Intensive Induction and Consolidation Chemotherapy in Treatment Naïve AML

50 enrolled

Leukemia, Myeloid, Acute

NCT05342584 2026-01-08

Venetoclax AML

99 enrolled

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT04659616 2025-12-19

Pemigatinib After Chemotherapy for the Treatment of Newly Diagnosed Acute Myeloid Leukemia

32 enrolled

Leukemia, Myeloid, Acute

NCT04802161 2025-12-19

Comparing the Addition of an Anti-Cancer Drug, Pomalidomide, to the Usual Chemotherapy Treatment (Daunorubicin and Cytarabine Liposome) in Newly Diagnosed Acute Myeloid Leukemia With Myelodysplastic Syndrome-Related Changes

50 enrolled 12 charts

Myelodysplastic Syndromes, Myeloproliferative Disorders, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic

NCT05361057 2025-12-05

Efficacy of Venetoclax Based Regimen in Prevention Relapse of Consecutive MRD Positive AML Patients

Phase 2 Terminated

20 enrolled

Phase 3 Active not recruiting

Leukemia, Myeloid, Acute

NCT01371981 2025-11-26

Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia

1,645 enrolled 32 charts

Other hematologic neoplasmSarcoma

Leukemia, Myeloid, Acute, Sarcoma, Myeloid

NCT07232134 2025-11-20

AML-DS-2025

100 enrolled

Down Syndrome, Leukemia, Myeloid, Acute

NCT06451861 2025-11-17

Randomized Study of ABC-14 Regimen Compared With "3+7" Standard Induction Therapy or AB-14 for ND AML

240 enrolled

Phase 1/2 Active not recruiting

Leukemia, Myeloid, Acute

NCT04817241 2025-11-10

Testing Oral Decitabine and Cedazuridine (ASTX727) in Combination With Venetoclax for Higher-Risk Acute Myeloid Leukemia Patients

5 enrolled

LymphoidOther hematologic neoplasm

Leukemia, Myeloid, Acute

NCT03860844 2025-09-09

ISAKIDS

Phase 2 Terminated

67 enrolled 25 charts

Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT07131059 2025-08-20

MRD-positive AML Clinical Study

Phase NA Recruiting

120 enrolled

Phase 3 Active not recruiting

Leukemia, Myeloid, Acute, Neoplasm, Residual

NCT02521493 2025-08-01

Response-Based Chemotherapy in Treating Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome in Younger Patients With Down Syndrome

280 enrolled 13 charts

Down Syndrome, Myelodysplastic Syndromes, Myeloproliferative Disorders, Leukemia, Myeloid, Acute

NCT07078591 2025-07-28

Venetoclax-containing Therapy Combined With Microtransplant for Newly Diagnosed AML

50 enrolled

Phase 3 Active not recruiting

Leukemia, Myeloid, Acute

NCT03897127 2025-07-17

Study of Standard Intensive Chemotherapy Versus Intensive Chemotherapy With CPX-351 in Adult Patients With Newly Diagnosed AML and Intermediate- or Adverse Genetics

882 enrolled